Drug
Acoltremon clinical trials
Also written TRYPTYR®.
- studies test it
- 16
- open now
- 8
- in phase 3
- 6
- first study started
- 2017
Keep track of what changes. Save the acoltremon studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
16 studies that test it; most in 2025 (6)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2020 | 1 |
| 2022 | 3 |
| 2024 | 2 |
| 2025 | 6 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 2
- Phase 3
- 6
- Phase 4
- 8
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 8
Aerie Pharmaceuticals (4) · Alcon Research (3) · Southern College of Optometry (3) · Eye Research Associates, LLC (1) · University of South Florida (1) · Center for Sight Las Vegas (1) · NYU Langone Health (1) · Center For Sight (1)
Studies
Open first, then newest update. How each study uses acoltremon is read from its arms, and is right about nine times in ten.
Testing it · 16
- Contact Lens-Wearing Dry Eye Subjects Who Are Treated With Acoltremon 0.003%Not yet recruitingPhase 4Eye Research Associates, LLCNCT07848373Written as acoltremon 0.003%
- Effect of Acoltremon Ophthalmic Solution 0.003% on Tear Production and Symptoms in Patients With Tear Deficiency and Concurrent Neuropathic Corneal PainNot yet recruitingPhase 4University of South FloridaNCT07849803Written as acoltremon ophthalmic solution 0.003%
- TRYPTYR as a Treatment for Patients With Dry Eye Disease (DED)RecruitingPhase 4NYU Langone HealthNCT07732010Written as TRYPTYR (Acoltremon ophthalmic solution 0.003%)
- Evaluating a New Therapy for Dry Eye in Patients With Sjögren's SyndromeRecruitingPhase 4Center For SightNCT07277257Written as TRYPTYR (Acoltremon ophthalmic solution 0.003%)
- Investigator Initiated Trial Using Dry Eye Surveys to Evaluate and Better Understand FDA Approved Acoltremon Treatment for Dry Eye Disease in Real World Treatment Settings (DESERT)Not yet recruitingPhase 4Center for Sight Las VegasNCT07281950Written as acoltremon 0.003%
- Switching From Xiidra to TRYPTYRNot yet recruitingPhase 4Southern College of OptometryNCT07267481Written as acoltremon 0.003%
- Switching From Restasis to TRYPTYRNot yet recruitingPhase 4Southern College of OptometryNCT07267299Written as acoltremon 0.003%
- Impact of TRYPTYR on a Patient's Quality of Life and Ability to Perform WorkRecruitingPhase 4Southern College of OptometryNCT07266948Written as Acoltremon
- A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye DiseaseCompletedPhase 3Alcon ResearchNCT06544694Written as 0.003% AR-15512 ophthalmic solution
- A Study to Evaluate 0.003% AR-15512 Safety and Drop AttributesCompletedPhase 3Alcon ResearchNCT06660290Written as 0.003% AR-15512 ophthalmic solution
- A Study Designed to Evaluate Tear ProductionCompletedPhase 3Alcon ResearchNCT06544707Written as 0.003% AR-15512 ophthalmic solution
- A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512CompletedPhase 3Aerie PharmaceuticalsNCT05493111Written as 0.003% AR-15512 ophthalmic solution
- Study Evaluating the Safety and Efficacy of AR-15512 (COMET-3)CompletedPhase 3Aerie PharmaceuticalsNCT05360966Written as 0.003% AR-15512 ophthalmic solution
- Study Evaluating the Safety and Efficacy of AR-15512CompletedPhase 3Aerie PharmaceuticalsNCT05285644Written as 0.003% AR-15512 ophthalmic solution
- A Phase 2b Study Evaluating the Safety and Efficacy of AR-15512 Ophthalmic Solution for the Treatment of Dry Eye DiseaseCompletedPhase 2Aerie PharmaceuticalsNCT04498182Written as AR-15512 Ophthalmic Solution
- Assessing the Safety and Efficacy of AVX-012 in Subjects With Mild-to-moderate Dry Eye SyndromeStatus unknownPhase 1/2Avizorex Pharma, S.L.NCT03162094Written as AVX012 Ophthalmic Solution Low dose
Codes
What other systems call acoltremon · ClinicalTrials.gg INT002150
- MeSH (NLM) C000731855acoltremonOne source NLM
- UNII (FDA) 1L7BVT4Z4ZACOLTREMONConfirmed FDA, NLM, Wikidata
- Wikidata Q27089230acoltremonConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C189962AcoltremonOne source FDA
- DrugBank DB19202One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731855 | acoltremon | One source NLM |
| UNII (FDA) | 1L7BVT4Z4Z | ACOLTREMON | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27089230 | acoltremon | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C189962 | Acoltremon | One source FDA |
| DrugBank | DB19202 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.